Washington, D.C. — President Donald Trump announced today that AstraZeneca has agreed to lower prescription drug prices for Medicaid under a new deal with the Trump administration. The agreement, unveiled in the Oval Office, stipulates that AstraZeneca will provide all its medications to Medicaid at “most-favored-nation” prices—the lowest prices offered in other developed countries.
In addition to the Medicaid pricing, the deal includes provisions for direct-to-consumer sales through the upcoming TrumpRx.gov platform, allowing patients to purchase medications at reduced prices. AstraZeneca has committed to offering discounts of up to 80% off list prices for certain drugs, including inhalers for asthma and chronic obstructive pulmonary disease (COPD).
As part of the agreement, AstraZeneca will invest $50 billion in U.S. manufacturing and research and development by 2030, aiming to produce all its medicines sold in the U.S. domestically. In return, the company will receive a three-year exemption from tariffs on imported branded medicines.
The deal follows a similar agreement with Pfizer announced last month and is part of the administration’s broader effort to reduce prescription drug costs in the U.S. While the agreement is expected to benefit Medicaid patients, experts caution that broader systemic issues in drug pricing remain unaddressed.
Sources:
- AP News
- Reuters
- The Guardian
- Washington Post
- Financial Times
- Al Jazeera
- STAT News
- White House Fact Sheet
- AstraZeneca Press Release
Disclaimer
Artificial Intelligence Disclosure & Legal Disclaimer
AI Content Policy.
To provide our readers with timely and comprehensive coverage, South Florida Reporter uses artificial intelligence (AI) to assist in producing certain articles and visual content.
Articles: AI may be used to assist in research, structural drafting, or data analysis. All AI-assisted text is reviewed and edited by our team to ensure accuracy and adherence to our editorial standards.
Images: Any imagery generated or significantly altered by AI is clearly marked with a disclaimer or watermark to distinguish it from traditional photography or editorial illustrations.
General Disclaimer
The information contained in South Florida Reporter is for general information purposes only.
South Florida Reporter assumes no responsibility for errors or omissions in the contents of the Service. In no event shall South Florida Reporter be liable for any special, direct, indirect, consequential, or incidental damages or any damages whatsoever, whether in an action of contract, negligence or other tort, arising out of or in connection with the use of the Service or the contents of the Service.
The Company reserves the right to make additions, deletions, or modifications to the contents of the Service at any time without prior notice. The Company does not warrant that the Service is free of viruses or other harmful components.
